Prescription Drugs

House passes FDA bill increasing overseas inspections (CBS News)

May 30, 2012

(CBS/AP) WASHINGTON – In a move of bipartisanship, the House has passed a bill that would increase inspections of drug manufacturing facilities overseas, while also accelerating approval of new drugs at home. Under the House bill, passed 387-5 late Wednesday, the Food and Drug Administration would have more flexibility to inspect manufacturing sites in China, […]

continue reading »

Relief as US Senate passes drug user fee bill (PharmaTimes)

May 28, 2012

By Lynne Taylor Industry and consumer groups have welcomed the US Senate’s near-unanimous approval of legislation to reauthorise Food and Drug Administration (FDA) user fee agreements, and the House is expected to vote on a similar bill as early as this week. The FDA User Fee Reauthorization Bill (S 3187) is the “backbone” of  the […]

continue reading »

Vermont Senator Calls for Crackdown on Pharmaceutical Fraud (American News Report)

May 23, 2012

By Pat Anson Saying there is a “culture of fraud” in the pharmaceutical industry, Sen. Bernie Sanders (I-Vermont) has proposed tough new penalties against drug makers found guilty of fraud and off-label marketing of medication. Sanders’ amendment to a Food and Drug Administration bill would take away the company’s exclusive marketing rights to the drug […]

continue reading »

Vital prescription-drug bill plods though Senate (Nature News Blog)

By Amy Maxmen Lawmakers generally support the reauthorization of a piece of legislation that brings drugs to market at a reasonable pace. But as the Senate meets this week to vote on their iteration of the Prescription Drug User Fee Act (PDUFA), the discussion slows as they wade though 17 amendments to the act proposed […]

continue reading »

A breakthrough opportunity for global health (Business Day)

May 21, 2012

By Joseph E. Stiglitz Every year, millions of people die from preventable and treatable diseases, especially in poor countries. In many cases, lifesaving medicines can be cheaply mass-produced, but are sold at prices that block access to those who need them. And many die simply because there are no cures or vaccines, because so little […]

continue reading »

US Senate call to scrap drug patents (PharmaTimes)

By Lynne Taylor A leading US Senator has called for drug patent “monopolies” to be abolished and replaced by an annual prize fund to reward the discovery of new treatments which would then, because of the power of competitive markets, become available at the lowest possible price. “The US has – by far – the […]

continue reading »

Washington Post Calls a Free Market in Prescription Drugs “Radical” (Center for Economic & Policy Research)

May 20, 2012

The Washington Post showed that it clearly does not believe in free market fundamentalism. It ran an article on a bill proposed by Vermont Senator Bernie Sanders to replace patent monopolies for prescription drugs to treat AIDS with a prize system. The headline and second sentence of the piece described the system as “radical.” Under […]

continue reading »

‘Radical’ bill seeks to reduce cost of AIDS drugs by awarding prizes instead of patents (Washington Post)

May 19, 2012

By Brian Vastag Prizes, not patents. That could be the slogan for a radical idea that leading economists say would lower the price of new drugs for treating HIV/AIDS. Treating AIDS costs tens of thousands of dollars per patient annually in the United States, and more and more patients are unable to afford the life-saving […]

continue reading »

Bernie Sanders Offers Plan To Cut Prescription Drug Prices (HuffPost Politics)

By Zach Carter WASHINGTON — Sen. Bernie Sanders (I-Vt.) is promoting a new plan to encourage the development of better, cheaper prescription drugs: an innovation fund rewarding companies for inventing important new HIV and AIDS medications. In exchange for accepting an innovation award, drugmakers would agree to sell their new medicines at low prices. Drugs […]

continue reading »

A Breakthrough Opportunity for Global Health (Project Syndicate)

May 18, 2012

By Joseph E. Stiglitz NEW YORK – Every year, millions of people die from preventable and treatable diseases, especially in poor countries. In many cases, lifesaving medicines can be cheaply mass-produced, but are sold at prices that block access to those who need them. And many die simply because there are no cures or vaccines, […]

continue reading »

Page 1 of 212